Blockchain Registration Transaction Record

Quantum BioPharma to Present at ArcStone-Kingswood Summit, Eyes Phase 2 MS Trial

Quantum BioPharma (QNTM) to present at ArcStone-Kingswood Growth Summit. FDA clears Lucid-MS for Phase 2 MS trials. Learn more about QNTM's pipeline.

This news matters because Quantum BioPharma is advancing a first-in-class multiple sclerosis treatment, Lucid-MS, into Phase 2 trials after FDA clearance. With no approved therapies for progressive MS, a successful outcome could transform treatment paradigms and offer new hope to patients. For investors, the presentation at the ArcStone-Kingswood Growth Summit provides a window into Quantum’s strategy and upcoming catalysts, while the UNBUZZD™ royalty agreement adds a potential revenue stream. As the biotech sector continues to innovate, Quantum’s progress underscores the importance of supporting research into challenging neurodegenerative and metabolic disorders, which affect millions worldwide.